These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 11906546)
1. A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study. Benedetti Panici P; Greggi S; Amoroso M; Scambia G; Battaglia FA; Gebbia V; Salerno G; Paratore MP; Mancuso S Int J Gynecol Cancer; 2001; 11(6):438-44. PubMed ID: 11906546 [TBL] [Abstract][Full Text] [Related]
2. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Meyer T; Nelstrop AE; Mahmoudi M; Rustin GJ Ann Oncol; 2001 Dec; 12(12):1705-9. PubMed ID: 11843248 [TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®). Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331 [TBL] [Abstract][Full Text] [Related]
4. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a]. Kirchner HH; Atzpodien J; Poliwoda H Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119 [TBL] [Abstract][Full Text] [Related]
5. Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study. Sayal K; Gounaris I; Basu B; Freeman S; Moyle P; Hosking K; Iddawela M; Jimenez-Linan M; Abraham J; Brenton J; Hatcher H; Earl H; Parkinson C Int J Gynecol Cancer; 2015 Jul; 25(6):977-84. PubMed ID: 25962114 [TBL] [Abstract][Full Text] [Related]
6. Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum. Markman M; Webster K; Zanotti K; Peterson G; Kulp B; Belinson J Gynecol Oncol; 2004 Aug; 94(2):404-8. PubMed ID: 15297180 [TBL] [Abstract][Full Text] [Related]
10. Prognostic results of cisplatin IP and carboplatin IV with G-CSF in patients with ovarian cancer. Adachi S; Itani Y; Ito K; Noda T; Shintani M; Saito K; Furukawa N; Tomii Y Oncol Rep; 2001; 8(1):27-31. PubMed ID: 11115564 [TBL] [Abstract][Full Text] [Related]
11. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial. Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336 [TBL] [Abstract][Full Text] [Related]
13. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer]. Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544 [TBL] [Abstract][Full Text] [Related]
15. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents. Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA Oncology; 2013; 84(3):158-65. PubMed ID: 23296063 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial). Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657 [TBL] [Abstract][Full Text] [Related]
18. A systematic overview of chemotherapy effects in ovarian cancer. Högberg T; Glimelius B; Nygren P; Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940 [TBL] [Abstract][Full Text] [Related]
19. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer. Lund B; Hansen OP; Hansen HH; Hansen M Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618 [TBL] [Abstract][Full Text] [Related]